MRNA

#578
Moderna, Inc. Common Stock
52.84 USD
+4.26%
Sector: Atención Sanitaria
Básica: USD
Divisa de beneficio: USD
Rango diario
52.84
52.84
Rango anual
22.29
59.55
Cambio diario
+4.26%
Variación mensual
-1.05%
Variación en los últimos 6 meses
+99.10%
Cambio anual
+97.02%
Cierres anteriores
50.68
Abrir
52.84
Bid
Ask
Mínimo
52.84
High
52.84
Volumen
403
Ver el calendario completo

Financials

Visión general Informes Estadísticas
Trimestre Año
  • Market Capitalization 20.87 B
  • Employee 4 700
  • Founded N/A
  • CEO Stéphane Bancel
  • Website www.modernatx.com
  • Headquarter Delaware, United States
  • FIGI BBG003PHHZT1
  • Industry Technology
Ingresos totales
Beneficio neto
Beneficio básico por acción
Deuda total
Flujo de caja libre
Efectivo y equivalentes
Ratio precio/beneficio
-4.06
Relación precio/flujo de caja
5.9

Moderna Inc

Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern". The company's commercial products are the Moderna COVID-19 vaccine, marketed as Spikevax and a respiratory syncytial virus vaccine, marketed as Mresvia. The company has 44 treatment and vaccine candidates, of which 37 have entered clinical trials. Candidates include possible vaccines for influenza, HIV, Epstein–Barr virus, the Nipah virus, chikungunya, human metapneumovirus, varicella zoster virus, as well as a cytomegalovirus vaccine, a Zika virus vaccine funded by the Biomedical Advanced Research and Development Authority, and three cancer vaccines.

Noticias